Trials / Withdrawn
WithdrawnNCT02909569
Relieving Chronic Itch: Oral Medication
Relieving Chronic Itch : Oral Medication
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the effect of twice daily dose of INCB39110 in the treatment of itch in adults.
Detailed description
Chronic idiopathic itch accompanies low-grade skin inflammation. These inflammatory features are associated with cytokine production which signal through the common JAK1-STAT pathway. It is therefore theorized that a selective JAK1 inhibitor such as INCB039110 may provide relief of itch symptom.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB039110 | All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks. |
Timeline
- Start date
- 2018-08-01
- Primary completion
- 2018-10-09
- Completion
- 2018-10-09
- First posted
- 2016-09-21
- Last updated
- 2019-05-13
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02909569. Inclusion in this directory is not an endorsement.